EVOKE PHARMA, INC. Research and Development Expense
EVOKE PHARMA, INC. reported Research and Development Expense of $3.09 million for the 3-month period ending 2014-09-30, per its 10-Q filed 2014-11-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2014-11-13
- EVOKE PHARMA, INC. research and development expense for the quarter ending 2014-09-30 was $3.09M, a 3822.69% increase year-over-year.
- EVOKE PHARMA, INC. research and development expense for the quarter ending 2014-06-30 was $2.87M, a 2097.22% increase year-over-year.
- EVOKE PHARMA, INC. research and development expense for the quarter ending 2014-03-31 was $1.85M, a 1568.86% increase year-over-year.
- EVOKE PHARMA, INC. research and development expense for the quarter ending 2013-12-31 was $636.42K, a 99.91% increase year-over-year.
- EVOKE PHARMA, INC. research and development expense for fiscal 2013 was $956.98K, a 17.90% decline from fiscal 2012.
- EVOKE PHARMA, INC. research and development expense for fiscal 2012 was $1.17M, a 36.79% decline from fiscal 2011.
- EVOKE PHARMA, INC. research and development expense for fiscal 2011 was $1.84M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 80 month | Research and Development Expense 83 month | Research and Development Expense 86 month |
|---|---|---|---|---|---|---|---|
| 2014-09-30 | $3.09M 10-Q · filed 2014-11-13 | $5.96M derived: sum of 2 quarters · filed 2014-11-13 | $7.82M 10-Q · filed 2014-11-13 | $8.45M derived: sum of 4 quarters · filed 2014-11-13 | |||
| 2014-06-30 | $2.87M 10-Q · filed 2014-08-13 | $4.73M 10-Q · filed 2014-08-13 | $5.36M derived: sum of 3 quarters · filed 2014-08-13 | $5.44M derived: sum of 4 quarters · filed 2014-11-13 | |||
| 2014-03-31 | $1.85M 10-Q · filed 2014-05-13 | $2.49M derived: sum of 2 quarters · filed 2014-05-13 | $2.57M derived: sum of 3 quarters · filed 2014-11-13 | $2.70M derived: sum of 4 quarters · filed 2014-11-13 | $18.80M 10-Q · filed 2014-05-13 | ||
| 2013-12-31 | $636.42K 10-K · filed 2014-03-25 | $715.15K derived: sum of 2 quarters · filed 2014-11-13 | $846.00K derived: sum of 3 quarters · filed 2014-11-13 | $956.98K 10-K · filed 2014-03-25 | $16.95M 10-K · filed 2014-03-25 | ||
| 2013-09-30 | $78.73K 10-Q · filed 2014-11-13 | $209.58K derived: sum of 2 quarters · filed 2014-11-13 | $320.56K 10-Q · filed 2014-11-13 | $638.90K derived: sum of 4 quarters · filed 2014-11-13 | $16.31M 10-Q · filed 2013-11-13 | ||
| 2013-06-30 | $130.85K 10-Q · filed 2014-08-13 | $241.83K 10-Q · filed 2014-08-13 | $560.17K derived: sum of 3 quarters · filed 2014-08-13 | $897.18K derived: sum of 4 quarters · filed 2014-08-13 | |||
| 2013-03-31 | $110.98K 10-Q · filed 2014-05-13 | $429.33K derived: sum of 2 quarters · filed 2014-05-13 | $766.33K derived: sum of 3 quarters · filed 2014-05-13 | $979.34K derived: sum of 4 quarters · filed 2014-05-13 | |||
| 2012-12-31 | $318.35K 10-K · filed 2014-03-25 | $655.35K derived: sum of 2 quarters · filed 2014-03-25 | $868.36K derived: sum of 3 quarters · filed 2014-03-25 | $1.17M 10-K · filed 2014-03-25 | |||
| 2012-09-30 | $337.00K 10-K · filed 2014-03-25 | $550.01K derived: sum of 2 quarters · filed 2014-03-25 | $847.30K 10-Q · filed 2013-11-13 | ||||
| 2012-06-30 | $213.01K 10-K · filed 2014-03-25 | $510.30K derived: sum of 2 quarters · filed 2014-03-25 | |||||
| 2012-03-31 | $297.29K 10-K · filed 2014-03-25 | ||||||
| 2011-12-31 | $1.84M 10-K · filed 2014-03-25 |